Clinical Trials Logo

Staphylococcal Sepsis clinical trials

View clinical trials related to Staphylococcal Sepsis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04886284 Recruiting - Clinical trials for Staphylococcus Aureus Bacteremia

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

CERT
Start date: May 20, 2024
Phase: Phase 2
Study type: Interventional

There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

NCT ID: NCT00646399 Completed - Clinical trials for Staphylococcal Sepsis

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Start date: March 2009
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants. 1550 infants will be enrolled prior to 48 hours of life and will be randomized 1:1 to receive active drug or placebo on study days 0, 1, 2, 9, 16, and 23.

NCT ID: NCT00636285 Completed - Clinical trials for Staphylococcal Sepsis

Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants

Start date: April 2001
Phase: Phase 1
Study type: Interventional

The purpose of this Phase 1 study is to evaluate the safety and pharmacokinetics of BSYX-A110 in a small number of healthy adult volunteers. Following the demonstration of safety in adults, this anti-Staphylococcal monoclonal antibody will then be evaluated in the target population of hospitalized low birth weight neonates.

NCT ID: NCT00631800 Completed - Clinical trials for Staphylococcal Sepsis

Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

N003
Start date: May 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.